



Extracorporeal Shockwave Therapy Improves Functional Outcomes of Adhesive Capsulitis of the Shoulder in Patients With Diabetes

Diabetes Care 2017;40:e12–e13 | DOI: 10.2337/dc16-2063

Flavia Santoboni,^{1,2}
Stefano Balducci,^{3,4,5}
Valeria D'Errico,^{3,4,5} Jonida Haxhi,^{3,4,5}
Mario Vetrano,^{1,2} Giulia Piccinini,^{1,2}
Andrea Ferretti,^{1,6}
Giuseppe Pugliese,^{3,4} and
Maria Chiara Vulpiani^{1,2}

Adhesive capsulitis of the shoulder (ACS) is the most prevalent musculoskeletal disorder of the upper extremity (1,2) among people with diabetes. ACS is characterized by intense shoulder pain with progressive limitation of joint mobility and functional disability, negative impact on the quality of life, and increased health care costs (3). In the population without diabetes, treatment options include supervised physical therapy, oral or intra-articular steroid injections, extracorporeal shockwave therapy (ESWT), and arthroscopic capsular release (4). Oral or intra-articular steroids lead to rapid pain relief and improved range of motion (ROM), although benefits from steroids may not be maintained beyond 6 weeks in patients with diabetes (5). In addition, steroids can significantly increase glucose levels, thus affecting glycemic control in patients with diabetes. Therefore, it would be preferable to avoid steroids and opt for alternative therapies in these individuals. In view of the efficacy of ESWT for ACS in individuals without diabetes (4), we evaluated the effect of ESWT on functional outcomes in patients with diabetes with ACS.

Fifty consecutive patients with diabetes (7 with type 1 and 43 with type 2 diabetes, men:women ratio 70:30, mean \pm SD age

57.9 ± 13.0 years, disease duration 10.9 ± 7.9 years, HbA_{1c} $7.32 \pm 1.40\%$ [56.5 ± 15.3 mmol/mol], BMI 28.0 ± 5.3 kg/m², waist circumference 100.5 ± 13.2 cm) with ACS (pain duration 15.7 ± 13.2 months, in 70% of cases on side of the dominant hand) attending the Diabetes Unit of Sant'Andrea Hospital, Rome, Italy, were enrolled in this observational intervention trial. Inclusion criteria were known diabetes, shoulder pain, and ROM restriction ($>75\%$ ROM loss in ≥ 2 directions including abduction, flexion, external rotation, and internal rotation) for at least 3 months and no treatment other than analgesics within the past 3 months. In all patients, shoulder radiographs, soft-tissue sonography, and/or MRI studies were obtained at least 2 weeks before enrollment in the study. All patients received ESWT once a week for 3 weeks, 2,400 shots in an anterior-to-posterior direction on the anterior shoulder joint using a low/moderate energy flux density (0.06–0.14 mJ/mm², depending on individual pain tolerance). Functional outcome evaluations were performed using the Visual Analog Scale (VAS), the Constant Shoulder Score (CSS), and the Disabilities of the Arm, Shoulder and Hand Score

questionnaire (QuickDASH) at baseline (T₀) and after 2 (T₁), 4 (T₂), and 6 (T₃) months.

Over the study period, all functional outcomes improved markedly, with a 3.14-fold and 2.97-fold decrease of VAS and QuickDASH, respectively, and a 39.7% increase of CSS. Pairwise comparisons showed significant improvements even at T₁, with further amelioration of functional outcomes at T₂ and T₃, indicating that ESWT was beneficial both acutely and chronically (Table 1). No relevant side effects were reported throughout the study.

Though observational and uncontrolled, this pilot trial is, to the best of our knowledge, the first study assessing the effect of ESWT on functional outcomes in patients with diabetes with ACS. Results indicate that ESWT may be effective, feasible, and well tolerated and can therefore represent a valid alternative to steroids for ACS treatment in patients with diabetes. However, these findings need to be confirmed by a randomized controlled trial.

Acknowledgments. The authors thank the patients for their contribution.

¹Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy

²Physical Medicine and Rehabilitation Unit, Sant'Andrea Hospital, Rome, Italy

³Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy

⁴Diabetes Unit, Sant'Andrea Hospital, Rome, Italy

⁵Metabolic Fitness Association, Monterotondo, Rome, Italy

⁶Orthopaedic Unit and Kirk Kilgour Sports Injury Center, Sant'Andrea Hospital, Rome, Italy

Corresponding author: Maria Chiara Vulpiani, mariachiara.vulpiani@gmail.com.

Received 26 September 2016 and accepted 28 October 2016.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

Table 1—Functional evaluations at T₀, T₁, T₂, and T₃ and pairwise comparisons between time points

Functional outcomes	Assessment times*				Comparisons†					
	T ₀	T ₁	T ₂	T ₃	T ₀ vs. T ₁	T ₀ vs. T ₂	T ₀ vs. T ₃	T ₁ vs. T ₂	T ₁ vs. T ₃	T ₂ vs. T ₃
VAS	6.9 ± 1.6 (4–10)	5.2 ± 2.3 (1–9)	3.6 ± 2.3 (0–8)	2.2 ± 2.7 (0–8)	–1.74 (–1.15, –2.33), <0.001	–3.4 (–2.8, –3.99), <0.001	–4.78 (–4.04, –5.52), <0.001	–1.66 (–1.13, –2.19), <0.001	–3.04 (–2.24, –3.84), <0.001	–1.38 (–0.83, –1.93), <0.001
CSS	60.5 ± 13.9 (28–81)	68.7 ± 14.4 (38–91)	77.0 ± 13.8 (48–96)	84.5 ± 15.0 (28–98)	8.2 (5.2, 11.2), <0.001	16.5 (12.9, 20.2), <0.001	23.9 (19.0, 28.9), <0.001	8.3 (5.2, 11.5), <0.001	15.8 (10.6, 21.0), <0.001	7.5 (4.0, 10.9), <0.001
QuickDASH	48.7 ± 14.3 (25–77)	36.2 ± 7.6 (9–71)	24.8 ± 15.8 (5–64)	16.4 ± 19.4 (2–64)	–12.5 (–8.7, –16.4), <0.001	–23.9 (–19.4, –28.5), <0.001	–32.3 (–26.6, –37.9), <0.001	–11.4 (–7.6, –15.2), <0.001	–19.7 (–14.4, –25.0), <0.001	–8.3 (–5.1, –11.6), <0.001

*Mean ± SD (range). †Within-group difference (95% CI), P value.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. F.S., S.B., G.Pu., and M.C.V. contributed to the study concept and design. F.S., V.D., J.H., and G.Pi. contributed to acquisition of data. F.S., S.B., M.V., G.Pu., and M.C.V. contributed to analysis and interpretation of data. S.B. and G.Pu. drafted the manuscript. A.F. and M.C.V. contributed to the critical revision of the manuscript for important intellectual content. M.C.V. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Larkin ME, Barnie A, Braffett BH, et al.; Diabetes Control and Complications Trial/

Epidemiology of Diabetes Interventions and Complications Research Group. Musculoskeletal complications in type 1 diabetes. *Diabetes Care* 2014;37:1863–1869

2. Zreik NH, Malik RA, Charalambous CP. Adhesive capsulitis of the shoulder and diabetes: a meta-analysis of prevalence. *Muscles Ligaments Tendons J* 2016;6:26–34

3. Laslett LL, Burnet SP, Jones JA, Redmond CL, McNeil JD. Musculoskeletal morbidity: the growing burden of shoulder pain and disability and poor quality of life in diabetic outpatients. *Clin Exp Rheumatol* 2007;25:422–429

4. Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. *Clin Orthop Relat Res* 2000 (372):95–109

5. Buchbinder R, Green S, Youd JM, Johnston RV. Oral steroids for adhesive capsulitis. *Cochrane Database Syst Rev* 200;4:CD006189